

United States Patent and Trademark Office

119

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/564,520	01/13/2006	Keizo Sugasawa	03327.2338	3500
22852 FINNEGAN I		DERSON, FARABOW, GARRETT & DUNNER EXAMINER		INER
LLP	LLP		BARKER, M	MICHAEL P
	1 NEW YORK AVENUE, NW ASHINGTON, DC 20001-4413		ART UNIT	PAPER NUMBER
1			1626	
			MAIL DATE .	DELIVERY MODE
			11/23/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No. Applicant(s)		
Supplemental	10/564,520	SUGASAWA ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Michael P. Barker	1626	

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to <u>Amendment After Non-Fin. Rej. 14 Aug. 2007.</u> 2. The allowed claim(s) is/are 1 and 4-34. 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) 🔯 All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. _____. 3. \(\subseteq Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: . . Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) I including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date ___ (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. Notice of References Cited (PTO-892) 5. Notice of Informal Patent Application 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 6. ☐ Interview Summary (PTO-413). Paper No./Mail Date 3. Information Disclosure Statements (PTO/SB/08), 7. X Examiner's Amendment/Comment Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit 8.

Examiner's Statement of Reasons for Allowance of Biological Material 9. Other _____.

Application/Control Number: 10/564,520

Art Unit: 1626

DETAILED ACTION

· Claims 1 and 4-34 are pending in this Application and in condition for allowance.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Maryann Puglielli on 27 October 2007.

The application has been amended as follows:

Claim 11, p. 5, lines 4 and 9: Change, "pyridyl" to "pyridyl" (change the number one to a lowercase "L").

Claim 29, p. 11, line 1: After the words, "A method of regulating c-Mpl activity", insert the words, "for the treatment of throbocytopenia".

Specification, p. 81, (Table 28 Continued), No. A143: Delete, "cHex(Me)-", and insert, "cHexN(Me)-" therefor.

Response to Remarks

Applicant's amendments overcome the rejections and objections previously put forth.

The closest prior art has been made of record, thus no reasons for allowance are iterated here.

There is no art which anticipates or renders the instant Application obvious. Therefore,

Claims 1 and 4-34 are ALLOWED.

Application/Control Number: 10/564,520

Art Unit: 1626

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael P. Barker whose telephone number is (571) 272-4341. The examiner can normally be reached on Monday-Friday 8:00 AM- 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699. The unofficial fax phone for this group are (571) 273-8300.

Michael P. Barker

Patent Examiner, AU 1626

Technology Center 1600

REBECCA ANDERSON PRIMARY EXAMINER

(for) Joseph McKane

Supervisory Patent Examiner, AU 1626

Page 3

Technology Center 1600